Genmab reports Q2 2026 DARZALEX sales data
Genmab A/S reported that worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous formulation DARZALEX FASPRO, were USD 4,207 million for the second quarter of 2026.
Rhea-AI Filing Summary
Genmab A/S reported that worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous formulation DARZALEX FASPRO, were USD 4,207 million for the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.
Genmab receives royalties on these worldwide net sales of both intravenous and subcutaneous DARZALEX under an exclusive worldwide license granted to Johnson & Johnson’s Janssen Biotech to develop, manufacture and commercialize daratumumab. Genmab is an international biotechnology company focused on innovative antibody medicines for cancer and other serious diseases.
Positive
- None.
Negative
- None.
Filing Explained
The July 15 report is added to six existing S-8 registration statements, without disclosing a completed securities issuance.
The July 15 filing is a Form 6-K, which serves as a foreign private issuer’s interim report for material information published in its home market.
Its operative structural disclosure is that the report is incorporated by reference, from the filing date, into six listed Form S-8 registration statements, unless later documents supersede it. In practical terms, incorporation by reference makes this report part of those registration statements; the filing does not disclose an issuance or sale of securities.
The stated limitation is that the incorporation applies only to the extent the report is not superseded by subsequently filed or furnished documents.
Key Figures
DARZALEX net trade sales: USD 4,207 million
DARZALEX U.S. net trade sales: USD 2,435 million
DARZALEX rest of world net trade sales: USD 1,772 million
+3 more
6 metrics
DARZALEX net trade sales
USD 4,207 million
Worldwide net trade sales for the second quarter of 2026
DARZALEX U.S. net trade sales
USD 2,435 million
Net trade sales in the U.S. for the second quarter of 2026
DARZALEX rest of world net trade sales
USD 1,772 million
Net trade sales outside the U.S. for the second quarter of 2026
Years of operation
over 25 years
Period Genmab has advanced antibody-based therapeutic formats
Approved antibody medicines
eight
Number of approved antibody medicines powered by Genmab science
Established year
1999
Year Genmab was established
Key Terms
net trade sales, royalties, exclusive worldwide license, antibody–drug conjugates (ADCs), +2 more
6 terms
net trade sales financial
"worldwide net trade sales of DARZALEX ... were USD 4,207 million"
royalties financial
"Genmab receives royalties on the worldwide net sales of DARZALEX"
Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.
exclusive worldwide license regulatory
"under the exclusive worldwide license to J&J to develop, manufacture and commercialize"
antibody–drug conjugates (ADCs) medical
"including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies"
bispecific antibodies medical
"advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies"
Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.
immune-modulating antibodies medical
"antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities"
FAQ
What DARZALEX net sales did Genmab (GMAB) report for Q2 2026?
Genmab reported worldwide net trade sales of DARZALEX totaling USD 4,207 million for the second quarter of 2026. This included USD 2,435 million from the U.S. market and USD 1,772 million from the rest of the world, as reported by Johnson & Johnson.
How much of Q2 2026 DARZALEX sales came from the U.S. for Genmab (GMAB)?
U.S. net trade sales of DARZALEX were USD 2,435 million in the second quarter of 2026. Sales from the rest of the world were USD 1,772 million, bringing total worldwide DARZALEX net trade sales to USD 4,207 million for the period.
Does Genmab (GMAB) sell DARZALEX directly or receive royalties?
Genmab receives royalties on worldwide DARZALEX net sales rather than selling the product directly. Johnson & Johnson’s Janssen Biotech holds an exclusive worldwide license to develop, manufacture and commercialize daratumumab, and reports the DARZALEX net trade sales figures.
What products are covered by the DARZALEX royalty arrangement for Genmab (GMAB)?
The royalty arrangement covers both intravenous and subcutaneous DARZALEX products. This includes daratumumab and the subcutaneous formulation daratumumab and hyaluronidase-fihj, which is sold under the tradename DARZALEX FASPRO in the United States by Janssen Biotech.
What type of company is Genmab (GMAB) and where is it based?
Genmab is an international biotechnology company focused on innovative antibody medicines for cancer and other serious diseases. Established in 1999, it is headquartered in Copenhagen, Denmark, with an international presence across North America, Europe and the Asia Pacific region.
Who is Genmab’s (GMAB) partner for DARZALEX and how are sales reported?
Genmab’s partner for DARZALEX is Johnson & Johnson, through its legal entity Janssen Biotech, Inc.. Janssen Biotech develops, manufactures and commercializes daratumumab under an exclusive worldwide license and reports worldwide net trade sales on which Genmab receives royalties.
How many approved antibody medicines does Genmab (GMAB) say its science powers?
Genmab states that its science powers eight approved antibody medicines. The company has worked for over 25 years on a broad range of antibody-based formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation antibody modalities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JULY 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated July 15, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: July 15, 2026
Exhibit 99.1
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Company Announcement
•Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 million
•Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)
COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 4,207 million in the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 33 Page 1/1 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||